-
Integrin signalling in joint development, homeostasis and osteoarthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-16 Michael Z. Miao, Janice S. Lee, Kenneth M. Yamada, Richard F. Loeser
-
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-11 Megan P. Leask, Tania O. Crișan, Aichang Ji, Hirotaka Matsuo, Anna Köttgen, Tony R. Merriman
-
Itaconate targets fibroblast-like synoviocytes in RA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-10 Sarah Onuora
Treatment with the endogenous metabolite itaconate induced phenotypic and metabolic changes in fibroblast-like synoviocytes and reduced the severity of arthritis in an animal model.
-
Update on the pathophysiology and treatment of primary Sjögren syndrome Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-09 Chiara Baldini, Giovanni Fulvio, Gaetano La Rocca, Francesco Ferro
-
Pathogenic antibodies target stromal antigens in RA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-08 Jessica McHugh
New findings identify HSP60 and other synovial stromal-derived autoantigens as targets for pathogenic autoantibodies, exacerbating arthritis and serving as potential biomarkers.
-
Integrin-mediated ILC2 adhesion protects against lupus nephritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-08 Jessica McHugh
Type 2 innate lymphoid cells protect against kidney inflammation in lupus nephritis, and enhancing their adhesion via integrin α4β7 upregulation, particularly through IL-33 treatment, could be a promising therapeutic approach.
-
How muscle influences bone health Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-05 Maria Papatriantafyllou
FNIP1- and TFEB-dependent secretion of IGF2 by dystrophic muscles contributes to muscle–bone crosstalk.
-
Mitophagy as a link between ECM stiffness and chondrocyte senescence Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-21 Maria Papatriantafyllou
Ageing and excessive mechanical strain on the articular cartilage have both been associated with the development of knee osteoarthritis (OA). Cartilage degeneration in OA involves a senescent phenotype of chondrocytes, as well as modifications of the extracellular matrix (ECM). Research published in Bone Research investigates how mechanical signals in the form of altered ECM stiffness might lead to
-
Platelets in Kawasaki disease: mediators of vascular inflammation Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-17 Magali Noval Rivas, Begüm Kocatürk, Bernardo S. Franklin, Moshe Arditi
-
BiTEing refractory RA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-10 Jessica McHugh
The bispecific T cell engager (BiTE) blinatumomab showed promising clinical efficacy in a pilot study of six patients with multidrug-resistant rheumatoid arthritis.
-
Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-10 Christian D. DeMoya, Anisha Joenathan, Taylor B. Lawson, David T. Felson, Thomas P. Schaer, Manish Bais, Michael B. Albro, Janne Mäkelä, Brian D. Snyder, Mark W. Grinstaff
-
The peculiar features, diversity and impact of citrulline-reactive autoantibodies Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-10 Bruno Raposo, Lars Klareskog, William H. Robinson, Vivianne Malmström, Caroline Grönwall
-
Wearable device for RA management? Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-05 Maria Papatriantafyllou
A wearable smart device that uses reconfigurable electronics and conductive polymer-based microneedles was able to monitor inflammation and provide transdermal drug delivery and electrical stimulation in a rat model of arthritis.
-
COVID-19 linked to rise in anti-MDA5 autoimmunity Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-05 Jessica McHugh
Researchers have introduced the term ‘MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic’ (MIP-C) to describe cases of MDA5 autoimmunity that surged during the COVID-19 pandemic.
-
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-05 Sarah Onuora
New research provides a potential explanation for why long-term sclerostin neutralization leads to continued bone mass gain, despite attenuation of its short-term effects on bone formation.
-
Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-03 Frank Buttgereit, Andriko Palmowski, Milena Bond, Giovanni Adami, Christian Dejaco
-
Clarity for the language of race, ethnicity and genetic ancestry in rheumatology Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-31 Paula S. Ramos, S. Sam Lim
As the pace of genetic discovery has accelerated, so too has the need for clinicians and researchers to acknowledge and understand the impact of language in scientific publications. The use of inaccurate language contributes to systemic bias and eugenic ideologies that remain pervasive in biomedical science, including in rheumatology.
-
Two sides of management recommendations for psoriatic arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-21 Ennio Lubrano, Fabio Massimo Perrotta
Guidelines for the management of psoriatic arthritis (PsA) need to undergo revision to take on board new evidence, particularly in relation to therapeutics. In March 2024, EULAR published updated recommendations for the pharmacological treatment of PsA, and an expert group published consensus statements intended to complement existing guidelines.
-
Clinical phenotypes, molecular endotypes and theratypes in OA therapeutic development Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-17 Ali Mobasheri, Richard Loeser
-
Can transcriptomics guide the management of SLE-associated APS? Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-16 Jason S. Knight, Maria G. Tektonidou
The management of antiphospholipid syndrome is hindered by heterogeneous clinical presentations. Whole-blood transcriptomics have the potential to identify previously unknown disease endotypes, which could inform new treatment strategies. However, such hypothesis-generating data must still account for the results of randomized clinical trials, such as those focused on direct oral anticoagulants in
-
Recent advancements in cartilage tissue engineering innovation and translation Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-13 Rachel C. Nordberg, Benjamin J. Bielajew, Takumi Takahashi, Shuyan Dai, Jerry C. Hu, Kyriacos A. Athanasiou
-
Bone-modifying drugs slow OA progression Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-07 Sarah Onuora
Drugs used to treat osteoporosis could slow the progression of osteoarthritis, according to the findings of a study in mice.
-
Adropin inhibits fibrosis in SSc Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-03 Robert Phillips
The peptide hormone adropin, which is downregulated in dermal fibroblasts in patients with systemic sclerosis (SSc), inhibits TGFβ-mediated fibrosis in in vitro and ex vivo models of human skin, and has potential for the treatment of SSc.
-
Rethinking antiphospholipid syndrome to guide future management and research Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-03 Jason S. Knight, Doruk Erkan
Antiphospholipid syndrome (APS) consists of thrombotic, non-thrombotic and obstetric clinical manifestations developing in individuals with persistent antiphospholipid antibodies (aPL). Although researchers have made progress in characterizing different clinical phenotypes of aPL-positive people, the current approach to clinical management is still mostly based on a ‘one size fits all’ strategy, which
-
Relapsing polychondritis: clinical updates and new differential diagnoses Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-02 Philippe Mertz, Nathalie Costedoat-Chalumeau, Marcela A. Ferrada, Guillaume Moulis, Arsène Mekinian, Peter C. Grayson, Laurent Arnaud
-
Granzyme serine proteases in inflammation and rheumatic diseases Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-04-30 Alexandre Aubert, Karen Jung, Sho Hiroyasu, Julian Pardo, David J. Granville
-
Treat-to-target or treat-to-dissolve strategy to improve gout treatment Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-04-26 Pascal Richette, Nicola Dalbeth
Medication adherence in gout is low, and discontinuation of urate-lowering therapy puts patients at risk of flares and cardiovascular events. A strategy to regularly monitor serum urate levels and the dissolution of urate deposits (particularly if visualized by patients) might encourage adherence in the long term.
-
Advancing precision rheumatology through tissue and blood profiling Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-04-12 George D. Kalliolias, Athanasios G. Papavassiliou
-
Molecular biomarker approaches to prevention of post-traumatic osteoarthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-04-11 Virginia Byers Kraus, Ming-Feng Hsueh
-
Joint-specific memory, resident memory T cells and the rolling window of opportunity in arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-04-10 Margaret H. Chang, Robert C. Fuhlbrigge, Peter A. Nigrovic
-
Benralizumab noninferior to mepolizumab for EGPA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-04-09 Sarah Onuora
In a head-to-head phase III trial of two drugs that target IL-5 or its receptor, benralizumab was noninferior to mepolizumab for the induction of remission in patients with eosinophilic granulomatosis with polyangiitis.
-
Time for a new approach to drug development for rare systemic autoinflammatory diseases Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-04-02 Natalie M. Zitoun, Erkan Demirkaya, Raphaela Goldbach-Mansky, Micol Romano
Despite the transformative potential of treatments for systemic autoinflammatory diseases, these conditions remain underfunded and understudied. Urgent, coordinated action among stakeholders is needed to overcome regulatory and research barriers, as is innovation and advocacy for the development of effective therapies for these rare diseases.
-
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-03-27 Vanessa L. Kronzer, Jeffrey A. Sparks, Soumya Raychaudhuri, James R. Cerhan
-
Nanoparticle-based pazopanib shows promise in OA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-03-19 Rebecca Kelsey
A nanoparticle-based formulation of the anticancer drug pazopanib, which inhibits VEGFR1 and VEGFR2, shows promise as a disease-modifying drug for osteoarthritis.
-
Limitations of the updated EULAR recommendations for osteoarthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-03-18 Marius Henriksen
-
Evidence-Based Guideline for the management of osteoporosis in men Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-03-14 Nicholas R. Fuggle, Charlotte Beaudart, Olivier Bruyère, Bo Abrahamsen, Nasser Al-Daghri, Nansa Burlet, Manju Chandran, Mario M. Rosa, Bernard Cortet, Céline Demonceau, Willard Dere, Philippe Halbout, Mickaël Hiligsmann, John A. Kanis, Jean-Marc Kaufman, Andreas Kurth, Olivier Lamy, Andrea Laslop, Stefania Maggi, Radmila Matijevic, Eugene McCloskey, Ali Mobasheri, Maria C. Prieto Yerro, Régis P. Radermecker
-
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-03-12 Chio Yokose, Natalie McCormick, Abhishek Abhishek, Nicola Dalbeth, Tristan Pascart, Frédéric Lioté, Angelo Gaffo, John FitzGerald, Robert Terkeltaub, Meghan E. Sise, James L. Januzzi, Deborah J. Wexler, Hyon K. Choi
-
A nosology of immune diseases from deep immunophenotyping Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-03-11 Michael F. McDermott
-
All fibroblasts are equal, but some are more equal than others Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-03-11 Chrissy Bolton, Adam P. Croft
-
TYK2: an emerging therapeutic target in rheumatic disease Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-03-11 Eric Morand, Joseph F. Merola, Yoshiya Tanaka, Dafna Gladman, Roy Fleischmann
-
APOE in fat pad and synovium contributes to knee OA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-03-07 Robert Phillips
New research has identified apolipoprotein E expressed by fibroblasts and macrophages in the infrapatellar fat pad and synovium as a pathogenetic mediator and potential therapeutic target in knee osteoarthritis.
-
Immunogenic Xist ribonucleoproteins drive sex-biased autoimmunity Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-03-07 Jessica McHugh
Ribonucleoprotein complexes containing Xist, a long non-coding RNA involved in X chromosome inactivation, are immunogenic and promote autoimmune responses.
-
Eosinophils regulate bone remodelling Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-03-07 Sarah Onuora
Results of a new study indicate that eosinophils have a role in maintaining bone homeostasis through their inhibitory effects on bone-resorbing osteoclasts.
-
Genetically transitional disease: conceptual understanding and applicability to rheumatic disease Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-02-28 Timothy B. Niewold, Ivona Aksentijevich, Peter D. Gorevic, Greg Gibson, Qingping Yao
-
Targeting NP cell senescence in IVDD Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-02-26 Rebecca Kelsey
Intervertebral disc degeneration (IVDD) is responsible for about 40% of cases of low back pain, the leading cause of disability worldwide. Researchers in China report on a mechanism of IVDD progression whereby aberrant genomic DNA damage promotes senescence of nucleus pulposus (NP) cells, revealing a potential target that could improve IVDD outcomes. Intervertebral discs (IVDs) are avascular fibrocartilaginous
-
The therapeutic potential of immunoengineering for systemic autoimmunity Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-02-21 David A. McBride, Ryan M. Jones, Nunzio Bottini, Nisarg J. Shah
-
A critical view of WHO guidelines on management of low back pain Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-02-14 Mohamad Bittar, Atul Deodhar
The World Health Organization (WHO) has published new guidelines for the non-surgical management of chronic primary low back pain in adults in primary and community care settings. Although the guidelines are commendable, they lack guidance on when to suspect and how to avoid missing important secondary causes of back pain.
-
ZEB2 promotes formation of age-related B cells Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-02-08 Robert Phillips
Age-related B cells (ABCs) have pathogenic roles in autoimmune diseases. Research has now identified ZEB2 as the transcription factor that mediates differentiation into ABCs.
-
GWAS data help unravel Dupuytren disease Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-02-08 Sarah Onuora
A meta-analysis of data from six genome-wide association study cohorts implicates several signalling pathways, including Hedgehog and Notch signalling, in Dupuytren disease.
-
Deep learning in rheumatological image interpretation Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-02-08 Berend C. Stoel, Marius Staring, Monique Reijnierse, Annette H. M. van der Helm-van Mil
-
Sodium channel Nav1.7 regulates chondrocyte biology and OA progression Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-02-07 Jessica McHugh
The voltage-gated sodium channel Nav1.7 is expressed on chondrocytes, regulates chondrocyte biology and osteoarthritis progression, and is a promising dual target for modifying disease while providing pain relief in osteoarthritis.
-
Treatment of non-systemic juvenile idiopathic arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-02-06 Susan Shenoi, Gerd Horneff, Amita Aggarwal, Angelo Ravelli
In the past two decades, the treatment of juvenile idiopathic arthritis (JIA) has evolved markedly, owing to the availability of a growing number of novel, potent and relatively safe therapeutic agents and the shift of management strategies towards early achievement of disease remission. However, JIA encompasses a heterogeneous group of diseases that require distinct treatment approaches. Furthermore
-
The gut microbiome in systemic lupus erythematosus: lessons from rheumatic fever Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-02-06 Gregg J. Silverman, Doua F. Azzouz, Nicolas Gisch, Abhimanyu Amarnani
-
Factors identified that predict resolution of subclinical synovitis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-02-05 Jessica McHugh
New findings provide insight into the natural history of subclinical synovitis, a reported predictor of the development of rheumatoid arthritis, and identify various factors associated with its reversal.
-
Difficult-to-treat psoriatic arthritis: moving out of the rheumatoid arthritis shadow Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-01-26 Stefan Siebert, Helena Marzo-Ortega
As in rheumatoid arthritis, achieving low disease activity or remission in psoriatic arthritis (PsA) remains a challenge and unmet need for many individuals. However, the complex pathogenesis, heterogeneity and varied tissue involvement in PsA mean that dedicated definitions and novel solutions are required for difficult-to-treat disease.
-
Is cell therapy no better than steroid injection? Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-01-25 Scott A. Rodeo
New findings suggest that current cell therapy approaches are not superior to a simple corticosteroid injection for the treatment of osteoarthritis, calling into question the role of existing cell therapies and highlighting the need for further research and development in this field.
-
Immune tolerance of citrullinated peptides Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-01-23 Ranjeny Thomas, William H. Robinson
Re-establishing tolerance to autoantigens is an important aim for the treatment of rheumatoid arthritis (RA). Immunization of HLA-DR4 transgenic mice with citrullinated self-antigens can induce immune tolerance, which suggests that such antigens could have a therapeutic role in anti-citrullinated peptide antibody-positive RA.
-
Engineering approaches for RNA-based and cell-based osteoarthritis therapies Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-01-22 Carlisle R. DeJulius, Bonnie L. Walton, Juan M. Colazo, Richard d’Arcy, Nora Francini, Jonathan M. Brunger, Craig L. Duvall
-
Raynaud phenomenon: from GWAS to drug repurposing Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-01-16 Ariane L. Herrick, Gisela Orozco
The identification of novel risk variants in the largest genome-wide association study of Raynaud phenomenon to date provides insights into the pathophysiology of the condition, including the potential role for α2A-adrenoceptors, and suggests opportunities for drug repurposing.
-
Proposals for the rheumatological use of JAK inhibitors Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-01-12 Francesco Ciccia, Roberto Caporali